I alpha-hydroxycholecalciferol: a treatment of renal bone disease.
- 4 January 1975
- Vol. 1 (5948), 12-14
- https://doi.org/10.1136/bmj.1.5948.12-a
Abstract
Three patients with chronic renal failure on maintenance haemodialysis have been treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHCC), a synthetic vitamin D analogue. A daily dose of 2 mug by mouth produced a significant increase in both calcium absorption from the gastrointestinal tract and calcium content of bone. Treatment with 1 alpha-OHCC appears to be effective in cases of metabolic bone disease associated with chronic renal failure.Keywords
This publication has 23 references indexed in Scilit:
- The Kidney as an Endocrine Organ for the Production of 1,25-Dihydroxyvitamin D3, a Calcium-Mobilizing HormoneNew England Journal of Medicine, 1973
- Particle body neutron activation analysis in vivo: A new approach to the investigation of metabolic bone diseasePhysics in Medicine & Biology, 1973
- Comparison of the Stannous Chloride and Vanadate Methods for Estimation of Serum Inorganic Phosphorus by Use of the "SMA 12/60"Clinical Chemistry, 1973
- Determination of body composition by neutron activation analysis in patient with renal failure.1972
- Silver Staining of Bone Prior to Decalcification for Quantitative Determination of Osteoid in SectionsStain Technology, 1972
- NEUTRON-ACTIVATION ANALYSIS IN MAN IN VIVOThe Lancet, 1964
- BONE DISEASE IN CHRONIC RENAL FAILUREQJM: An International Journal of Medicine, 1963
- A MODIFIED BONE-BIOPSY DRILL FOR OUTPATIENT USEThe Lancet, 1963
- THE TREATMENT OF RENAL-GLOMERULAR OSTEODYSTROPHYQJM: An International Journal of Medicine, 1961
- AZOTAEMIC RENAL OSTEODYSTROPHYBritish Medical Bulletin, 1957